S62798 / Servier - LARVOL DELTA

S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism. (PubMed, Thromb Res) - "In vivo, curative S62798 intravenous treatment, alone or associated with heparin, accelerated clot lysis by potentiating endogenous fibrinolysis and thus decreased pulmonary fibrin clots. S62798 is expected to be a therapeutic option for pulmonary embolism patients on top of anticoagulants."

Journal • Preclinical • Cardiovascular • Hematological Disorders • Pulmonary Embolism • Respiratory Diseases • Venous Thromboembolism

[VIRTUAL] S62798, a TAFIa inhibitor, accelerates endogenous thrombolysis in a murine model of pulmonary thromboembolism (ESC 2020) - "Due to its capacity to enhance endogenous fibrinolysis, S62798, which has completed phase I studies, is expected to be a therapeutic option for intermediate high risk PE patients on top of anticoagulants. With early recanalization, S62798 should rapidly reduce pulmonary artery pressure and resistance, with concomitant improvement in right ventricular function, preserving cardiac function, and reducing acute PE-related morbidity and mortality in these patients."

Preclinical • Cardiovascular • Pulmonary Embolism • Venous Thromboembolism • F2

[VIRTUAL] Favourable safety profile of S62798, a potent TAFIa (activated thrombin-activatable fibrinolysis inhibitor) inhibitor, in first-in-man study in healthy subjects (ESC 2020) - "S62798, a potent TAFIa inhibitor, has a favourable safety profile with a linear PK. PD results on TAFIa inhibition and clot lysis assay suggest that S62798 has relevant properties to pursue clinical development as an enhancer of endogenous fibrinolysis for the treatment of thromboembolic diseases"

Clinical • Cardiovascular • Pulmonary Embolism • Venous Thromboembolism • F2

A study to find the appropriate dose of S62798 to treat patients with pulmonary circulation blocked by a clot (clinicaltrialsregister.eu) - P2; N=370; Ongoing; Sponsor: Institut de Recherches Internationales Servier

Clinical • New P2 trial